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ABSTRACT
Introduction: Community-based voluntary counselling
and testing (CBVCT) services for men who have sex
with men (MSM) can reach those most-at-risk and
provide an environment for gay men that is likely to be
non-stigmatising. Longitudinal data on the behaviour of
HIV-negative MSM are scarce in Europe. The aim of
this protocol, developed during the Euro HIV Early
Diagnosis And Treatment (EDAT) project, is to
implement a multicentre community-based cohort of
HIV-negative MSM attending 15 CBVCT services in 5
European countries.
Research objectives: (1) To describe the patterns of
CBVCT use, (2) to estimate HIV incidence, and to
identify determinants of (3) HIV seroconversion and
(4) HIV and/or sexually transmitted infection (STI)
test-seeking behaviour.
Methods and analysis: All MSM aged 18 years or
over and who had a negative HIV test result are invited
to participate in the COmmunity-BAsed Cohort (COBA-
Cohort). Study enrolment started in February 2015,
and is due to continue for at least 12 months at each
study site. Follow-up frequency depends on the testing
recommendations in each country (at least 1 test per
year). Sociodemographic data are collected at baseline;
baseline and follow-up questionnaires both gather data
on attitudes and perceptions, discrimination, HIV/STI
testing history, sexual behaviour, condom use, and
pre- and post-exposure prophylaxis. Descriptive,
exploratory and multivariate analyses will be performed
to address the main research objectives of this study,
using appropriate statistical tests and models. These
analyses will be performed on the whole cohort data
and stratified by study site or country.
Ethics and dissemination: The study was approved
by the Public Health authorities of each country where
the study is being implemented. Findings from the
COBA-Cohort study will be summarised in a report to
the European Commission, and in leaflets to be
distributed to study participants. Articles and
conference abstracts will be submitted to peer-reviewed
journals and conferences.
INTRODUCTION
In the European Economic Area, the annual
rate of HIV diagnoses has remained relatively
stable since 2004, with 32 605 new cases
reported in 2014 (6.4/100 000 population)
when adjusted for reporting delay.1 In those
countries consistently reporting data, the
proportion of new infections due to
Strengths and limitations of this study
▪ This study is the first pan-European multicentre
prospective cohort of HIV-negative men who
have sex with men (MSM) enrolling participants
in community-based counselling and testing
services.
▪ The COmmunity-BAsed Cohort (COBA-Cohort) is
recruiting a sample of HIV-negative MSM
expected to be larger than 4000 individuals, col-
lecting HIV test results and other common data
on testing patterns and sexual behaviour.
▪ The prospective design of the COBA-Cohort will
allow causal relationships to be inferred with
appropriate statistical analysis.
▪ Representativeness will be the main limitation of
this study; the final sample will not be represen-
tative of the whole European MSM population
but only of those individuals attending the par-
ticipating sites.
▪ Long-term data collection may be limited in
several sites due to scarce financial resources.
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male-to-male sexual transmission increased from 30% in
2005 to 42% in 2014, while decreasing in all other
known transmission groups.1 In Western Europe, seven
countries reported an estimated HIV prevalence in
MSM of more than 10% in 2012, ranging from 17.7% in
France to 10.2% in Portugal.2
Although men who have sex with men (MSM) remain
one of the most affected populations for HIV in Europe,
direct incidence estimates are scarce because very few
cohort studies have been conducted. Those incidence
data that are available show that HIV is still spreading
rapidly among MSM, with slightly different estimates
between countries: 1.2/100 person-years (PYs) in
Amsterdam (the Netherlands) in 2014,3 3.1/100 PYs in
Barcelona (Spain) in 20114 and 2.8/100 PYs in Lisbon
(Portugal), between 2011 and 2014.5
Under the current ‘combination prevention’ para-
digm, based on behavioural, biomedical and structural
interventions, improving access to and frequency of HIV
testing has become one of the main strategies to
improve HIV prevention in MSM. Indeed, there is
strong evidence of the beneﬁts of early diagnosis and
subsequent treatment for individuals (lower mortality
and morbidity, higher quality of life, improved life
expectancy and overall health) and populations (both
behaviour change and antiretroviral therapy reducing
onward transmission risk).6 Although the evidence for
reduced sexual risk reduction after HIV testing and
counselling in those with a negative test is weaker, a
recent study suggested that frequent HIV testing helps
HIV-negative MSM to talk more openly about HIV status
with their sexual partners, which in turn may reduce ser-
odiscordant condomless anal intercourse.7
Frequent voluntary counselling and testing for HIV
and other sexually transmitted infections (STIs) in MSM
has been recommended for about 10 years.8 9 Both
WHO and European Centre for Disease Prevention and
Control (ECDC) recently reminded that annual HIV/
STI testing for sexually active MSM is a minimum, and
should be more frequent for those having condomless
anal sex with multiple or anonymous partners.10 11
Despite these recommendations, the observed propor-
tions of MSM tested within the previous 12 months in
the European MSM Internet Survey (EMIS) ranged
from 20% in Lithuania to 47% in France,12 13 suggesting
that there is considerable scope to increase frequent
HIV testing within combined prevention Public Health
strategies.
Barriers to the uptake of HIV (re-)testing are well
known and may exist at individual, health provider and
institutional levels.6 MSM face additional, speciﬁc bar-
riers to testing, such as homophobia and internalised
homonegativity.13–17 To help overcome these barriers,
many European countries have implemented or at least
authorised community-based voluntary counselling and
testing (CBVCT) services (as deﬁned in the HIV-
COBATEST project: HIV COmmunity-BAsed TESTing
practices in Europe18) targeting key populations,
including MSM. CBVCT services targeting MSM manage
to reach those most at risk,19–21 probably because peer
counselling is well adapted to the culture of MSM, under-
stands their practices, and addresses homophobia and
worries of rejection. Several studies have also shown that
CBVCT has contributed to increasing testing frequency
among MSM19 20 and has improved linkage to care.22 23
Conducting longitudinal studies within CBVCT ser-
vices is challenging because their work is focused on
HIV testing and prevention activities, and the systems
employed to guarantee anonymity may hinder identiﬁca-
tion of returning individuals. Although data are rou-
tinely collected by CBVCT services to monitor their
testing activity, these are often underexploited and
report test positivity rates rather than the proportion of
users who test positive for HIV.
This study protocol thus proposes to implement a
service-based cohort of HIV-negative MSM among atten-
dees of existing CBVCT services targeting MSM, taking
into account the experience of two existing cohorts of
MSM in CBVCT services.4 24 The protocol was developed
within the Euro HIV Early Diagnosis And Treatment
project (Euro HIV EDAT: https://eurohivedat.eu/),
cofunded by the Consumers, Health, Agriculture and
Food Executive Agency (CHAFEA, European
Commission). Euro HIV EDAT builds on experience
and expertise from the HIV-COBATEST project (study
reports available at http://cobatest.org) in which a
network of European CBVCT services was developed to
share experience and improve early diagnosis in key
populations such as MSM.
To the best of our knowledge, this study—the
COmmunity-BAsed Cohort (COBA-Cohort)—is the ﬁrst
pan-European longitudinal study involving CBVCT ser-
vices sharing the same data collection tool and recruit-
ment procedures. It is thus a unique occasion to improve
the comparability of incidence data between European
countries and to disentangle the observed similarities
and peculiarities in the determinants of seroconversion
between countries.
METHODS AND ANALYSIS
General study design
This COBA-Cohort is a pan-European prospective and
multicentre cohort of HIV-negative MSM attending 1 of
the 15 participating CBVCT services, led by ﬁve non-
governmental organisations (NGOs): AIDES,
AIDS-Fondet, Ath Checkpoint, CheckpointLX and
Legebitra, from France, Denmark, Greece, Portugal and
Slovenia, respectively (ﬁgure 1). The current protocol
was developed, discussed and agreed on by a working
group that includes the coordinating centre (Centre
for Epidemiological Studies on HIV/STI of Catalonia
(CEEISCAT), Barcelona, Spain), at least one represen-
tative of the previously mentioned NGOs and three
representatives from external academic institutions
(Institute of Tropical Medicine Antwerp in Belgium;
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the Institute of Public Health of the University of Porto
in Portugal and the Slovenian Institute of Public
Health).
The main challenge in developing the protocol of the
COBA-Cohort study was to harmonise the methodo-
logical procedures and tools in order to obtain compar-
able data, while maintaining the operative autonomy of
the participating CBVCT services. This observational
service-based cohort does not aim to change any of the
usual procedures of the participating sites, for instance
HIV testing recommendations or counselling and testing
methods. The follow-up frequency of participants hence
depends on the participants’ willingness to return for
a test.
Objectives
The main research objectives of this service-based study
in MSM are (1) to describe the patterns of CBVCT use,
(2) to identify determinants of HIV and/or STI test-
seeking behaviour (including repeat testing), (3) to esti-
mate the HIV incidence and (4) to identify risk factors
for seroconversion.
Furthermore, determinants for sexual risk behaviour
and coinfections could also be described.
Feasibility
The existence of two ongoing HIV-negative MSM
cohorts in CBVCT services, at BCN Checkpoint in
Barcelona4 and CheckpointLX in Lisbon,24 demon-
strates the feasibility of running a service-based
pan-European cohort, enrolling and following up MSM
within established CBVCT services. CheckpointLX,
which is also participating in COBA-Cohort, established
and runs the MSM Lisbon Cohort and was enrolling
around 600 new participants per year until 2014, taking
into account a 30% refusal rate.
The ﬁrst sites of COBA-Cohort started enrolling parti-
cipants in early 2015, and the total sample included
2313 individuals by 29 February 2016. Other start dates
and interim raw data for each CBVCT service are pre-
sented in table 1. As the enrolment phase started only
a few weeks before this date in several sites, the corre-
sponding samples are still very small.
These raw data show that CheckpointLX is now
recruiting many more participants per year than in pre-
vious years, and has a stable refusal rate of 30%.
In smaller centres such as Legebitra (Ljubljana,
Slovenia), which performed 480 HIV tests in 2014, the
refusal rate is much lower (around 11%). Apart from
Figure 1 Community-based voluntary counselling and testing (CBVCT) services participating in the COmmunity-BAsed Cohort
(COBA-Cohort).
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the personal motivation of the Slovenian CBVCT users
to participate in a research study, this refusal rate may be
lower than that of CheckpointLX because they can take
advantage of the systematic waiting time before the test
to ﬁll in the questionnaire. Additionally, peer counsel-
lors may have more time per attendee because the
annual number of tests is smaller than at the other sites.
Inclusion criteria and recruitment
Inclusion criteria are as follows: reporting any kind of
sex with another man at least once in the 12 months
prior to enrolment, being 18 years or older, being a resi-
dent or frequent visitor to the CBVCT service catchment
area, having a negative HIV test result at enrolment and
providing written consent.
All men attending the participating CBVCT services who
meet the inclusion criteria during the recruitment period
are offered participation in the cohort. Potential partici-
pants are given speciﬁc information about the
COBA-Cohort and the implications of participation
(verbal and written explanations) before giving their
written informed consent. CBVCT service attendees who
meet the inclusion criteria but decline participation are
asked to complete a short questionnaire, to be ﬁlled in
either by the attendee himself or by a counsellor during a
face-to-face interview (the refusal questionnaire included
the following variables: date of the current test, gender,
date and country of birth, country of residence, education,
occupation, deﬁnition of sexual orientation, date of the
last HIV test, main reasons for not participating).
The aim is to make the convenience sample as large
as possible (expected to be larger than 4000 partici-
pants), and as representative as possible of each site (an
essential pre-requisite for descriptive and analytic objec-
tives). Within the framework of Euro HIV EDAT, the
enrolment phase was due to start in January 2015 and to
end in June 2016 at each site (18 months). However, the
start of the cohort has been delayed in almost all sites
(see table 1) due to difﬁculties in preparing the ﬁeld-
work (translations, trainings, pilots, etc) and/or in
obtaining the ethics approval.
Nevertheless, all participating CBVCTs already
expressed their willingness to continue the recruitment
after the originally planned deadline. Those sites that
started in 2015 will thus recruit for 18 months (same
duration as originally planned), and the others will
recruit for a total of at least 12 months.
Follow-up
Recommendations for testing frequency differ between
countries and CBVCT services, but they all recommend
having at least one test per year, the frequency usually
varying according to the risk proﬁle. Enrolled partici-
pants are encouraged to be retested according to these
recommendations. Proactive follow-up (calls, SMS,
emails, etc), which has already been implemented in
several participating CBVCT services, would also be
Table 1 Interim enrolment data between the start and 29 February 2016 (raw data)
NGOs
CBVCT
services
Start dates
(mm/dd/yyyy)
Eligible men
invited to
participate
Participants
enrolled
Users who
declined
participation*
Participants
who returned
at least once†
n n n (%) n (%)
CheckpointLX
(Portugal)
Lisbon 01/02/2015 1748 1219 529 (30.3) 220 (18.0)
Legebitra
(Slovenia)
Ljubljana 02/09/2015 324 287 37 (11.4) 69 (24.0)
AIDS-Fondet Copenhagen 04/13/2015 697 624 73 (10.5) 107 (17.1)
(Denmark) Aarhus 05/07/2015 66 52 14 (21.2) 18 (34.6)
AIDES Paris 12th 01/05/2016 8 8 0 (0) 0 (0)
(France) Lyon 01/06/2016 16 15 1 (6.3) 1 (6.7)
Montpellier 01/07/2016 13 12 1 (7.7) 1 (8.3)
Paris 8th 01/13/2016 7 7 0 (0) 0 (0)
Marseille South 01/14/2016 20 19 1 (5.0) 0 (0)
Marseille North 01/15/2016 5 5 0 (0) 0 (0)
Lille 01/20/2016 13 12 1 (7.7) 0 (0)
Paris 2nd 01/21/2016 6 6 0 (0) 1 (16.7)
Nice 01/22/2016 32 18 14 (43.8) 0 (0)
Paris 19th 01/27/2016 9 8 1 (11.1) 0 (0)
Ath Checkpoint
(Greece)
Athens 02/15/2015 33 21 12 (36.4) 0 (0)
Total 15 sites 01/02/2015 2997 2313 684 (22.8) 417 (18.0)
*May be under-reported in several sites.
†May include duplicates in several sites.
CBVCT, community-based voluntary counselling and testing; NGO, non-governmental organisation.
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offered to all study participants in order to improve
repeat testing rates for those accepting reminders.
At each follow-up visit, participants undergo HIV
testing and peer counselling, and are offered prevention
supplies (condoms, lubricants, brochures, etc) by the
CBVCT services. In case of a reactive test during
follow-up, participants are offered a conﬁrmation test in
accordance with country diagnosis guidelines. In some
of the participating CBVCT services, the conﬁrmatory
test can be conducted onsite. In others, participants are
referred to a laboratory or health facility for conﬁrma-
tory testing and access to standard public HIV care in
their country. Linkage to care procedures in European
CBVCT services are being investigated as part of another
work package of the Euro HIV EDAT project.
COBA-Cohort participants will be followed up at least
until the end of the study period planned in the Euro
HIV EDAT project (March 2017). However, all partici-
pating CBVCT services are aware of the importance of
continuing the follow-up in such a study. Some have
already expressed their willingness to continue the
follow-up beyond this date.
The study group is currently exploring opportunities
to obtain extra funds and/or ﬁnding alternative solu-
tions that could reduce the workload linked to participa-
tion in the COBA-Cohort. In particular, as data entry is
one of the most time-consuming tasks for the participat-
ing CBVCT services, the possibility of using new tech-
nologies such as online or tablet-based self-administered
questionnaires is being investigated to overcome this
barrier to long-term participation.
Data collection
A common version of each questionnaire (baseline,
follow-up and refusal) has been developed and agreed
on by the working group. In all but one CBVCT service,
questionnaires are self-administered. Participants have to
ﬁll in a sociobehavioural questionnaire at inclusion
(baseline questionnaire) and a shorter version
(follow-up questionnaire) every time they return to the
CBVCT service.
These questionnaires collect data on the sociodemo-
graphic proﬁle (baseline questionnaire only), general
health and HIV risk, HIV testing (history, patterns, inten-
tions and attitudes), sexual behaviour (history, type of part-
ners, condom use, partner’s serological status data, etc),
STIs, and hepatitis B and C (history, testing patterns and
vaccines), and pre- and post-exposure prophylaxis (aware-
ness, use and intention to use). Several questions also gath-
ered information about alcohol and drug use during sex
(type of drugs and frequency) as well as history of injecting
drug use (whether or not related to sex, including the
date of the last injection).
In the baseline questionnaire, questions refer to ‘the
past 12 months’ and ‘since the last visit’ in the follow-up
questionnaire. Indeed, as the frequency of follow-up is
not ﬁxed (eg, visiting every 6 months), follow-up ques-
tions about participants’ behaviour prior to their visits
refer to ‘since the last visit’ in order to cover all the
exposure time between two visits. The original question-
naires were developed in English, and then translated by
each NGO into their local language(s) before piloting
them internally.
During each visit, CBVCT providers also collect data
about the general characteristics of each participant’s
visit (counselling, type of test, conﬁrmatory testing), bio-
medical data (test and conﬁrmatory test results, access to
the results) and linkage to care (if applicable). These
indicators are mainly derived from the standardised
form currently used in the European COBATEST
network of CBVCT services.25 26
Data management
To facilitate sharing and harmonisation of the data gath-
ered through the self-administered questionnaires, the
coordinating centre has implemented a web-based data
collection tool (secured by an https connection protocol)
enabling CBVCT service providers to enter the paper
questionnaires online. Nevertheless, each participating
CBVCT service can also use its own data collection
approach. Indeed, as CheckpointLX already had its own
data collection tool, its use was continued. In France,
AIDES developed a tablet-based self-administered ques-
tionnaire to be ﬁlled in by the enrolled participants
themselves because CBVCT service providers are not
allowed to enter the participants’ questionnaire data
under current French ethical guidelines. Since this latter
model of data collection would considerably reduce the
time dedicated to COBA-Cohort in each site, the study
group aims to generalise it in the coming months.
For the moment, CBVCT services using the paper
questionnaires must perform regular data entry of the
inclusion, follow-up and refusal questionnaires. This
allows the coordinating centre to centralise the data
every 6 months in order to monitor the study and
perform interim analyses. In the CBVCT services using
their own data collection tool, cumulative data sets in a
pre-established format are sent to the coordinating
centre, to be merged with the rest of the data.
According to local data protection laws and ethical
guidelines, personal identiﬁable information of the parti-
cipants (name, email address, etc) may be collected locally
by the CBVCT service to remind participants to come back
for a test, but such data are not entered into the central
cohort database managed by the coordinating centre;
each participant will only be identiﬁed by an anonymous
unique participant identiﬁer in the cohort database.
Statistical analysis
The study aims to recruit a convenience sample of
CBVCT service users that is as representative as possible,
offering participation in the study to all eligible MSM
attending the participating CBVCT services during the
recruitment period, and collecting basic sociodemo-
graphic data for those declining participation.
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The sociodemographic proﬁle of MSM declining to
participate will be compared with that of those enrolled
in the cohort study and should any signiﬁcant differ-
ences be found between both groups, the ﬁnal sample
will be weighted to compensate for selection bias. The
estimated weight to be applied will be computed as the
inverse of the probability of participation on the basis of
the sociodemographic data.
Descriptive analyses will then be performed on each
variable in order to describe the activity and the main
characteristics of the cohort (for the total cohort and
separately for each CBVCT service or NGO).
Other descriptive, exploratory or multivariate analyses
will be performed to address the main research objec-
tives of this study (patterns of use of CBVCT, HIV/STI
testing behaviour and sexual risk taking). χ2 Tests will be
used to compare categorical variables, and Student’s
t-test or Mann-Whitney U test for continuous variables,
as appropriate.
The HIV incidence rate (with 95% CI) will be esti-
mated for the total cohort and if sample size allows for
each CBVCT service or NGO among participants having
at least one follow-up visit. The follow-up time of partici-
pants will start at the date of the baseline visit and end
at the date of HIV seroconversion or last HIV-negative
test. The incidence will thus correspond to the number
of HIV seroconversions (ie, a ﬁrst positive HIV test after
a negative HIV test in a previous visit) divided by PYs of
follow-up. We will also identify factors associated with
HIV seroconversion, using multivariate Cox regression
models. HRs and their 95% CIs will be computed.
In longitudinal analyses, differences in the period of
time between visits will be taken into account by using
the appropriate statistical models (eg, generalised esti-
mating equation and mixed-effects models).
ETHICS AND DISSEMINATION
The coordinating centre and all NGOs except Ath
Checkpoint have been involved in the HIV-
COBATEST,18 also funded by the European
Commission. The coordinating centre and several part-
ners of the present study have also taken part in other
European projects such as SIALON27 28 and EMIS.13
The ﬁrst study results will be published at the end of
the Euro HIV EDAT study period (September 2017) in a
report for the CHAFEA, European Commission. This
report will address all the research objectives of this study,
and will be published after approval from the steering
committee members and the advisory board of the Euro
HIV EDAT project. A brochure based on the main study
results will be published and translated into various lan-
guages in order to be distributed by the participating
CBVCT services to the men who took part in the cohort.
At the end of the recruitment period, a ﬁrst scientiﬁc
article describing the COBA-Cohort proﬁle will be pub-
lished in a peer-reviewed journal, and other articles and
conference abstracts will be submitted to international
journals and conferences to disseminate the results of
speciﬁc analyses. Regular brochures for participants will
provide an insight into the evolution of the cohort.
APPLICABILITY AND PERSPECTIVES
The implementation of such a cohort of HIV-negative
MSM in different European countries, sharing method-
ology and data, should contribute to improved scientiﬁc
knowledge of the uptake of community-based testing,
HIV and STI testing patterns, and the trends in HIV
testing and sexual behaviours over time, and from test to
test in this population. It will also be an opportunity to
compare the behaviour and attitudes of MSM between
countries and in various contexts (including health
systems), highlighting the speciﬁc characteristics of each
local situation.
These data will be crucial to design better preventive
interventions aiming at increasing test uptake among
MSM. HIV incidence data are also very important mea-
sures that will help in identifying the speciﬁc subgroups
that are even more affected by HIV. Indeed, a recent
cohort study showed that it was possible to identify sub-
groups of MSM with a much higher incidence, even in
low-incidence contexts.29 The results will also contribute
to increased knowledge of the care cascade in Europe,
in particular in those sites where data regarding linkage
to care are available.
Some of the main challenges of this pan-European
multicentre prospective cohort of HIV-negative MSM are
(1) to make it sustainable over time and (2) to include
other CBVCT services in order to better reﬂect the
diversity of European MSM. At the time of publication
of this article, the study group was already in contact
with other European CBVCT services that would be
willing to join the study.
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